Leflunomide in clinical practice.

47Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

Leflunomide (LEF) is a prodrug that is rapidly converted to its active metabolite A77 1726, that inhibits the novo pyrimidine nucleotide biosynthesis, mediated especially by the dihydroorotate dehidrogenase (DHODH). DMARD properties were documented in rheumatoid arthritis with efficacy, safety and limiting of radiological progression demonstrated in multiple studies. LEF has been also used in other autoimmune diseases, like Psoriatic Arthritis, Wegener granulomatosis, Systemic Lupus Erythematosus, Sarcoidosis and others. This article reviews the place of LEF in clinical practice and outlines its potential applications beyond the officially recognized indication: rheumatoid arthritis (RA).

Cite

CITATION STYLE

APA

Pinto, P., & Dougados, M. (2006). Leflunomide in clinical practice. Acta Reumatológica Portuguesa. https://doi.org/10.14412/1996-7012-2014-1-59-63

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free